Tarsus Pharmaceuticals Statistics
Share Statistics
Tarsus Pharmaceuticals has 38.23M shares outstanding. The number of shares has increased by 1.94% in one year.
| Shares Outstanding | 38.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.58M |
| Failed to Deliver (FTD) Shares | 1.89K |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 7.54M, so 19.73% of the outstanding shares have been sold short.
| Short Interest | 7.54M |
| Short % of Shares Out | 19.73% |
| Short % of Float | 23.15% |
| Short Ratio (days to cover) | 12.17 |
Valuation Ratios
The PE ratio is -4.38 and the forward PE ratio is -22.14.
| PE Ratio | -4.38 |
| Forward PE | -22.14 |
| PS Ratio | 34.1 |
| Forward PS | 3.3 |
| PB Ratio | 3.02 |
| P/FCF Ratio | -4.84 |
| PEG Ratio | n/a |
Enterprise Valuation
Tarsus Pharmaceuticals Inc. has an Enterprise Value (EV) of 401.80M.
| EV / Earnings | -2.96 |
| EV / Sales | 23.03 |
| EV / EBITDA | -3.05 |
| EV / EBIT | -2.81 |
| EV / FCF | -3.27 |
Financial Position
The company has a current ratio of 6.93, with a Debt / Equity ratio of 0.15.
| Current Ratio | 6.93 |
| Quick Ratio | 6.85 |
| Debt / Equity | 0.15 |
| Total Debt / Capitalization | 13.15 |
| Cash Flow / Debt | -3.94 |
| Interest Coverage | -42.78 |
Financial Efficiency
Return on equity (ROE) is -0.69% and return on capital (ROIC) is -62.59%.
| Return on Equity (ROE) | -0.69% |
| Return on Assets (ROA) | -0.51% |
| Return on Capital (ROIC) | -62.59% |
| Revenue Per Employee | 71.50K |
| Profits Per Employee | -556.94K |
| Employee Count | 244 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.51 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 95.93% in the last 52 weeks. The beta is 1, so Tarsus Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1 |
| 52-Week Price Change | 95.93% |
| 50-Day Moving Average | 50.38 |
| 200-Day Moving Average | 36.41 |
| Relative Strength Index (RSI) | 28.56 |
| Average Volume (20 Days) | 765.54K |
Income Statement
In the last 12 months, Tarsus Pharmaceuticals had revenue of 17.45M and earned -135.89M in profits. Earnings per share was -4.62.
| Revenue | 17.45M |
| Gross Profit | 15.85M |
| Operating Income | -143.16M |
| Net Income | -135.89M |
| EBITDA | -131.67M |
| EBIT | -143.16M |
| Earnings Per Share (EPS) | -4.62 |
Balance Sheet
The company has 224.95M in cash and 31.73M in debt, giving a net cash position of 193.22M.
| Cash & Cash Equivalents | 224.95M |
| Total Debt | 31.73M |
| Net Cash | 193.22M |
| Retained Earnings | -244.66M |
| Total Assets | 376.30M |
| Working Capital | 291.25M |
Cash Flow
In the last 12 months, operating cash flow was -117.49M and capital expenditures -1.50M, giving a free cash flow of -123.00M.
| Operating Cash Flow | -117.49M |
| Capital Expenditures | -1.50M |
| Free Cash Flow | -123.00M |
| FCF Per Share | -4.19 |
Margins
Gross margin is 90.87%, with operating and profit margins of -820.53% and -778.89%.
| Gross Margin | 90.87% |
| Operating Margin | -820.53% |
| Pretax Margin | -778.89% |
| Profit Margin | -778.89% |
| EBITDA Margin | -754.69% |
| EBIT Margin | -820.53% |
| FCF Margin | -704.96% |
Dividends & Yields
TARS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.43% |
| FCF Yield | -7.26% |
Analyst Forecast
The average price target for TARS is $60, which is 35.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $60 |
| Price Target Difference | 35.4% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 8.18 |
| Piotroski F-Score | 3 |